Free Trial

Heron Therapeutics (HRTX) News Today

$3.44
-0.03 (-0.86%)
(As of 05/24/2024 ET)
Heron Therapeutics (NASDAQ:HRTX) Reaches New 12-Month High at $3.36
Heron Therapeutics (NASDAQ:HRTX) Reaches New 12-Month High at $3.36
Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post FY2026 Earnings of $0.20 Per Share
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities researchers at Capital One Financial upped their FY2026 earnings estimates for shares of Heron Therapeutics in a research note issued on Wednesday, May 15th. Capital One Financial analyst T. Chiang now expects that the biotechnology
Heron Therapeutics (NASDAQ:HRTX) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC restated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Up 7.3% in April
Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 27,290,000 shares, a growth of 7.3% from the April 15th total of 25,430,000 shares. Based on an average trading volume of 2,350,000 shares, the days-to-cover ratio is presently 11.6 days.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Monaco Asset Management SAM
Monaco Asset Management SAM grew its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 219.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,226,475 shares of the biotechnology co
Q2 2024 EPS Estimates for Heron Therapeutics, Inc. Raised by Northland Capmk (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities research analysts at Northland Capmk lifted their Q2 2024 earnings estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now anticipat
Heron Therapeutics (NASDAQ:HRTX) Rating Reiterated by Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday.
Heron Therapeutics Inc. Q1 Loss decreases, beats estimates
Heron Therapeutics earnings preview: what to expect
Heron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on Tuesday
Heron Therapeutics (NASDAQ:HRTX) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588518)
Equities Analysts Offer Predictions for Heron Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report released on Tuesday, April 23rd. Capital One Financial analyst T. Chiang forecasts that the biotec
Heron Therapeutics (NASDAQ:HRTX) Coverage Initiated at Capital One Financial
Capital One Financial started coverage on Heron Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $6.00 price objective for the company.
Congress Park Capital LLC Purchases 1,209,500 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)
Congress Park Capital LLC increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 205.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,798,650 shares of the biotechnology company's sto
Heron Therapeutics (NASDAQ:HRTX) Shares Pass Above Two Hundred Day Moving Average of $1.67
Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above 200 Day Moving Average of $1.67
HRTX Apr 2024 1.500 call
Heron Therapeutics Soars After 4Q Earnings Beat
Q4 2023 Heron Therapeutics Inc Earnings Call
Heron Therapeutics (NASDAQ:HRTX) Given New $5.00 Price Target at Needham & Company LLC
Needham & Company LLC increased their target price on shares of Heron Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Wednesday.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. raised its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 100.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,000,000 shares of the biotechnolo
What Wall Street expects from Heron Therapeutics's earnings
Preview: Heron Therapeutics's Earnings
Heron Therapeutics (HRTX) to Release Quarterly Earnings on Tuesday
Heron Therapeutics (NASDAQ:HRTX) will be releasing earnings after the market closes on Tuesday, March 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=571447)
Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

$1,500 to $9,400 in one month? (A.I. Trade List) (Ad)

This brand new A.I. Machine finds stocks and options trades which have had nearly PERFECT WIN RATES and gains as high as 1729%*

Click here to reserve your free seat

HRTX Media Mentions By Week

HRTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HRTX
News Sentiment

0.74

0.44

Average
Medical
News Sentiment

HRTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HRTX Articles
This Week

11

2

HRTX Articles
Average Week

Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:HRTX) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners